miRNA Signature in Small Extracellular Vesicles and their Association with Platinum Resistance and Cancer Recurrence in Ovarian Cancer
Carboplatin, administered as a single drug or in combination with paclitaxel, is the standard chemotherapy treatment for patients with ovarian cancer (OVCA). Recent evidence suggests that miRNAs associated with small extracellular vesicles (sEVs) participate in the development of chemoresistance. We studied the effect of carboplatin in a heterogeneity population of OVCA cells and their derived sEVs to identify mechanisms associated with chemoresistance. sEVs were quantified using an engineered superparamagnetic material, gold-loaded ferric oxide nanotubes and a screen-printed electrode. miR-21-3p, miR-21-5p, and miR-891-5p are enriched in sEVs, and they contribute to carboplatin resistance in OVCA. Using a quantitative MS/MS, miR-21-5p activates glycolysis and increases the expression of ATP-binding cassette family and a detoxification enzyme. miR-21-3p and miR-891-5p increase the expression of proteins involved in DNA repair mechanisms. Interestingly, the levels of miR-891-5p within sEVs is significantly higher in patients at risk of ovarian cancer relapse. Identification of miRNAs in sEVs also provides the opportunity to track them in biological fluids to potentially determine patient response to chemotherapy.
|Título de la Revista:||NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE|
|Fecha de publicación:||2020|
|Notas:||On 1/4/20, 12:47 am, "firstname.lastname@example.org on behalf of Nanomedicine NBM" <email@example.com> wrote: Ms. Ref. No.: JN202011R1 Title: miRNA Signature in Small Extracellular Vesicles and their Association with Platinum Resistance and Cancer Recurrence in Ovarian Cancer Nanomedicine: Nanotechnology, Biology, and Medicine Dear Dr. Salomon, Thank you for submitting your manuscript to the journal Nanomedicine: NBM. The Editors appreciate your efforts, and we are pleased to accept the manuscript for publication. Further comments from the editors and reviewers, if any, are appended below. The uncopyedited, uncorrected manuscript will soon be available online as an Article In Press and indexed in PubMed. Before publication, you will receive the proof of your manuscript and further information* from the publisher, Elsevier, Inc. Please read the proof carefully and contact the publisher if anything is unclear or incorrect; the authors have final responsibility for the accuracy of the publication. Congratulations. Best regards, Anil K. Sood, MD Associate Editor Tatiana Bronich, Ph.D. Editor-in-Chief Nanomedicine: Nanotechnology, Biology, and Medicine http://www.nanomedjournal.com/|